Genetic Signatures Limited (ASX:GSS)

Market Cap	32.94M -77.9%
Revenue (ttm)	19.75M +43.5%
Net Income	-20.10M
EPS	-0.09
Shares Out	227.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,108
Average Volume	246,304
Open	0.1400
Previous Close	0.1450
Day's Range	0.1350 - 0.1400
52-Week Range	0.1350 - 0.6900
Beta	0.72
RSI	22.11
Earnings Date	Feb 26, 2026

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GSS

Financial Performance

In fiscal year 2025, Genetic Signatures's revenue was 19.75 million, an increase of 43.47% compared to the previous year's 13.77 million. Losses were -20.10 million, 12.6% more than in 2024.